Dapagliflozin is a highly selective, reversible and potent inhibitor of the
sodium-glucose-linked Transporter 2 (SGLT2), which was successfully investigated for its use
as a treatment option in type 2 diabetes mellitus. The effect of dapagliflozin is an
increased glucosuria, and it was shown that mean blood glucose concentrations and
postprandial glucose excursion in special were significantly reduced in type 2 diabetic
patients. Due to its mechanism-of action it seems likely that also type 1 diabetic patients
will benefit from dapagliflozin. The present study is focused on the effects of dapagliflozin
on fasting glucose homeostasis and postprandial glucose excursion in male type 1diabetic
patients. Participants will subsequently receive 10 milligrams of dapagliflozin and placebo
for 3 days (equals 2 x 30mg per cross-over period) in a double-blind, randomised, cross-over
design. The effects will be measured via euglycemic hyperinsulinemic clamp studies (fasting
glucose homeostasis) and euglycemic oral glucose tolerance clamp tests (postprandial glucose
excursions).